Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA infant formula proposed QC batch-testing possibly "burdensome," Sandoz asserts.

This article was originally published in The Tan Sheet

Executive Summary

FDA INFANT FORMULA PROPOSED BATCH-TESTING "BURDENSOME," SANDOZ ARGUES, if it requires full analytical testing for every nutrient in each batch of formula. In Oct. 4 comments, Sandoz Nutrition tells the agency that it is unsure whether the proposed quality control procedures for infant formulas mean that: "a) the manufacturer must conduct full analytical testing on every nutrient in every batch; or b) the manufacturer would test each batch for a premix tracer plus full analytical testing on any nutrients added independently from premixes."





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts